Reported Sunday, Revolution Medicines' Zoldonrasib Demonstrates 52% Objective Response Rate And 93% Disease Control Rate In Previously Treated KRAS G12D Non-Small Cell Lung Cancer At AACR 2026

Benzinga Newsdesk www.benzinga.com Positive 88.3%

Neg 0% Neu 0% Pos 88.3%

Comments

No comments yet. Be the first!